



## SEQUENCE LISTING

RECEIVED  
SEP 21 2001  
TECH CENTER 1600/2900

<110> SAIKAWA, Akira  
IGARI, Yasutaka  
HATA, Yoshio  
YAMAMOTO, Kazumichi

<120> Sustained-Release Composition, Method of its Preparation and Use Thereof

<130> 2500USOP

<140> 09/582,926

<141> 2000-07-05

<150> PCT/JP99/00086

<151> 1999-01-13

<150> JP 10-6412

<151> 1998-01-16

<160> 5

<170> PatentIn version 3.0

<210> 1

<211> 11

<212> PRT

<213> artificial

<220>

<223> LH-RH derived peptide

<220>

<221> MOD\_RES

<222> (1)..(1)

<223> X is 5-oxo carboxy terminal

<220>

<221> MOD\_RES

<222> (7)..(7)

<223> X is "Y" which can be DLeu, DALa, DTrp, DSer(tbut), D2Nal or DHis  
(ImBzl

<220>

<221> MOD\_RES

<222> (11)..(11)

<223> X is "Z" which can be NH-C2H5 or Gly-NH2

<400> 1

Xaa Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa  
1 5 10

<210> 2

<211> 11  
<212> PRT  
<213> artificial

<220>  
<223> LH-RH antagonist derivatives

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> X is "X" which can be N(4H2-furoyl)Gly or NAc

<220>  
<221> MOD\_RES  
<222> (2)..(2)  
<223> X is D2Nal

<220>  
<221> MOD\_RES  
<222> (3)..(3)  
<223> X is D4ClPhe

<220>  
<221> MOD\_RES  
<222> (4)..(4)  
<223> X is D3Pal

<220>  
<221> MOD\_RES  
<222> (6)..(6)  
<223> X is "A" which can be NMeTyr, Tyr, Aph(Atz) or NMeAph(Atz)

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> X is "B" which can be DLys(Nic), DCit, DLys(AzaGlyNic), DLys(AzaGlyFur), DhArg(Et2), DAph(Atz), or DhC

<220>  
<221> MOD\_RES  
<222> (9)..(9)  
<223> X is "C" which can be Lys(Nisp), Arg or HArg(Et2)

<220>  
<221> MOD\_RES  
<222> (11)..(11)  
<223> X is DAlaNH2

<400> 2

Xaa Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa  
1 5 10

<210> 3  
<211> 10  
<212> PRT  
<213> artificial

<220>  
<223> LH-RH derived peptides

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> X is 5-oxo carboxy terminal

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> X is DLeu

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> X is NH-C2H5 amino terminal

<400> 3

Xaa Pro His Trp Ser Tyr Xaa Arg Pro Xaa  
1 5 10

<210> 4  
<211> 12  
<212> PRT  
<213> artificial

<220>  
<223> LH-RH derived peptides

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> X is N-(S)-tetrahydrofur-2-oyl-

<220>  
<221> MOD\_RES  
<222> (3)..(3)  
<223> X is D2Nal

<220>  
<221> MOD\_RES

<222> (4)..(4)  
<223> X is D4ClPhe

<220>  
<221> MOD\_RES  
<222> (5)..(5)  
<223> X is D3Pal

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> X is NMeTyr

<220>  
<221> MOD\_RES  
<222> (8)..(8)  
<223> X is DLys(Nic)

<220>  
<221> MOD\_RES  
<222> (10)..(10)  
<223> X is Lys(Nisp)

<220>  
<221> MOD\_RES  
<222> (12)..(12)  
<223> X is DALaNH2

<400> 4

Xaa Gly Xaa Xaa Xaa Ser Xaa Xaa Leu Xaa Pro Xaa  
1 5 10

<210> 5  
<211> 11  
<212> PRT  
<213> artificial

<220>  
<223> LH-RH derived peptides

<220>  
<221> MOD\_RES  
<222> (1)..(1)  
<223> X is 5-oxo carboxy terminal

<220>  
<221> MOD\_RES  
<222> (7)..(7)  
<223> X is DLeu

<220>

<221> MOD\_RES

<222> (11)..(11)

<223> X is NH-C2H5 amino terminal

<400> 5

Xaa Pro His Trp Ser Tyr Xaa Leu Arg Pro Xaa

1

5

10